Cardiff Oncology, Inc. (CRDF) intrinsic value & 10-year financials
Cardiff Oncology, Inc. (CRDF) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 5.0% a year to $593.0K, with an average return on invested capital of 197.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.90
- Market cap
- $60.2M
- Revenue (FY2025)
- $593.0K
- Revenue growth (10-yr CAGR)
- 5.0%
- ROIC (10-yr avg)
- 197.1%
- Free cash flow (FY2025)
- -$38.0M
CRDF 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $593.0K | -$45.9M | -$0.69 | -$38.0M | -8256.3% | -162.4% |
| FY2024 | $683.0K | -$45.4M | -$0.95 | -$37.8M | -7123.1% | -118.9% |
| FY2023 | $488.0K | -$41.4M | -$0.93 | -$31.5M | -9305.7% | -64.2% |
| FY2022 | $386.0K | -$38.7M | -$0.89 | -$34.8M | -10337.3% | -35.8% |
| FY2021 | $359.0K | -$28.3M | -$0.73 | -$23.2M | -8037.6% | -45.0% |
| FY2020 | $366.0K | -$19.3M | -$1.08 | -$16.5M | -5214.7% | 789.2% |
| FY2019 | $244.6K | -$16.4M | — | -$13.3M | -6817.8% | 983.4% |
| FY2018 | $378.3K | -$16.5M | -$8.26 | -$13.2M | -4507.6% | 1104.3% |
| FY2017 | $505.4K | -$24.9M | -$0.72 | -$23.4M | -5064.4% | -279.6% |
| FY2016 | $381.1K | -$39.2M | -$1.37 | -$31.9M | -10534.9% | -200.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cardiff Oncology, Inc. has demonstrated mature, steady growth, with revenue compounding at 5.0% annually over the past decade.
Cardiff Oncology, Inc. has historically struggled to out-earn its cost of capital, averaging just -24.1% ROIC.
Cardiff Oncology, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cardiff Oncology, Inc. is modeled at 5.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-11.06 per share.